OCULAR THERAPEUTIX, INC Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
OCULAR THERAPEUTIX, INC (OCUL) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $902.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $879.00K, a 67.75% increase year-over-year.
- OCULAR THERAPEUTIX, INC proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $0.00.
- OCULAR THERAPEUTIX, INC proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-12-31 was $524.00K, a 21.02% increase year-over-year.
- OCULAR THERAPEUTIX, INC proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-09-30 was $0.00.
- OCULAR THERAPEUTIX, INC proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $1.59M, a 56.69% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $1.02M, a 19.39% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $851.00K, a 9.47% decline from fiscal 2022.
- OCULAR THERAPEUTIX, INC proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $940.00K, a 4.57% decline from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $902.00K 10-Q · filed 2026-08-03 | |||
| 2025-12-31 | $879.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $879.00K derived: sum of 2 quarters · filed 2026-02-05 | $1.59M 10-K · filed 2026-02-05 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $713.00K 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | $713.00K 10-Q · filed 2026-08-03 | |||
| 2024-12-31 | $524.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $524.00K derived: sum of 2 quarters · filed 2026-02-05 | $1.02M 10-K · filed 2026-02-05 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $492.00K 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $492.00K 10-Q · filed 2025-08-05 | |||
| 2023-12-31 | $433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $433.00K derived: sum of 2 quarters · filed 2026-02-05 | $851.00K 10-K · filed 2026-02-05 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $418.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $418.00K 10-Q · filed 2024-08-07 | |||
| 2022-12-31 | $458.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $458.00K derived: sum of 2 quarters · filed 2025-03-03 | $940.00K 10-K · filed 2025-03-03 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $482.00K 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $482.00K 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | $495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $495.00K derived: sum of 2 quarters · filed 2024-03-11 | $985.00K 10-K · filed 2024-03-11 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $490.00K 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $490.00K 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $397.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $397.00K derived: sum of 2 quarters · filed 2023-03-06 | $747.00K 10-K · filed 2023-03-06 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $350.00K 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $350.00K 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $157.00K derived: sum of 2 quarters · filed 2022-02-28 | $451.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $294.00K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $294.00K 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $178.00K derived: sum of 2 quarters · filed 2020-03-12 | $297.00K 10-K · filed 2020-03-12 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $119.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $119.00K 10-Q · filed 2019-08-07 | |||
| 2017-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $119.00K derived: sum of 2 quarters · filed 2020-03-12 | $276.00K 10-K · filed 2020-03-12 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $157.00K 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $157.00K 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $150.00K derived: sum of 2 quarters · filed 2019-03-07 | $278.00K 10-K · filed 2019-03-07 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $128.00K 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $128.00K 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $101.00K derived: sum of 2 quarters · filed 2018-03-08 | $249.00K 10-K · filed 2018-03-08 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $148.00K 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $148.00K 10-Q · filed 2016-08-09 | |||
| 2014-12-31 | $64.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |